{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:34Z","timestamp":1792800754364,"version":"4.5.0"},"reference-count":0,"publisher":"Index Copernicus","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2020,4,7]]},"abstract":"<jats:p>Introduction: Background: Diverticulosis is the most common finding in the GI tract. Nearly half of the people with diverticula\nexperience symptomatic uncomplicated diverticular disease (SUDD).\nAims: The primary endpoints of our study were to assess the effectiveness of combined therapy with rifaximin-\u03b1 and\narabinogalactan-lactoferrin in symptom reduction and normalization of bowel movements. The secondary endpoints were\nan assessment of efficacy in SUDD recurrence prevention and patients\u2019 compliance to the combined therapy.\nMethods: A retrospective observational survey study was performed in 2019 among physicians experienced in diverticular\ndisease (DD) treatment in Poland. Patients with previous episodes of recurrences treated with combined therapy (cyclic\nrifaximin-\u03b1 at least 400 mg b.i.d\/7 days\/every month and continuous arabinogalactan-lactoferrin supplementation 1 sachet\ndaily) were assessed after 3 and 6 months regarding symptoms\u2019 resolution in the three-point scale. The patients\u2019 SUDD history,\ndiagnostic methods, treatment, and results, as well as patients\u2019 compliance were evaluated.\nResults: 281 patients met inclusion criteria, and were further evaluated (67.6% women, median age 65 years). After 6 months\nof combined treatment, there was a statistically significant reduction in the total severity score (median from 1.7 [max 3 points] to\n0.26; P &lt; 0.0001; sum from 8.5 [max 15 points] to 1.28; P &lt; 0.0001) and improvement in each symptom score. Stool frequency\nstatistically normalized in every group. As many as 31.7% had complete symptom resolution. Patients\u2019 compliance with the\ntherapy was very good and good in 92.9% of cases.\nC onclusions and discussion: Combination therapy with cyclic rifaximin-\u03b1 and continuous arabinogalactan combined with\nlactoferrin are effective in SUDD treatment in terms of symptom resolution, bowel movement normalization, prevention of\nrecurrences with very good patient\u2019s compliance.<\/jats:p>","DOI":"10.5604\/01.3001.0014.0946","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T14:11:08Z","timestamp":1587391868000},"page":"22-28","source":"Crossref","is-referenced-by-count":9,"title":["Combined therapy: rifaximin-\u03b1 and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease"],"prefix":"10.5604","volume":"92","author":[{"given":"Anna Maria","family":"Pietrzak","sequence":"first","affiliation":[{"name":"Klinika Gastroenterologii Onkologicznej, Narodowy Instytut Onkologii im. Marii Sk\u0142odowskiej-Curie, Pa\u0144stwowy Instytut Badawczy w Warszawie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Banasiewicz","sequence":"additional","affiliation":[{"name":"Katedra i Klinika Chirurgii Og\u00f3lnej, Endokrynologicznej i Onkologii Gastroenterologicznej, Uniwersytet Medyczny w Poznaniu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Skoczylas","sequence":"additional","affiliation":[{"name":"Klinika Gastroenterologii Onkologicznej, Narodowy Instytut Onkologii im. Marii Sk\u0142odowskiej-Curie, Pa\u0144stwowy Instytut Badawczy w Warszawie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dziki","sequence":"additional","affiliation":[{"name":"Klinika Chirurgii Og\u00f3lnej i Kolorektalnej, Uniwersytecki Szpital Kliniczny im. WAM w \u0141odzi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Szczepkowski","sequence":"additional","affiliation":[{"name":"Klinika Chirurgii Kolorektalnej, Og\u00f3lnej i Onkologicznej, Centrum Medyczne Kszta\u0142cenia Podyplomowego w Warszawie"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0014.0946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0014.0946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T14:11:09Z","timestamp":1587391869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0014.0946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,7]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0014.0946","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}